Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Total Revenue of $84.04 million for fiscal year 2025.
ELITE PHARMACEUTICALS INC /NV/ — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $84.04M +48.4% |
$56.63M +65.8% |
$34.16M +5.9% |
$32.26M +27.1% |
$25.38M +41.0% |
$17.99M +137.8% |
| Revenue (ASC 606) | $84.04M +48.4% |
$56.63M +65.8% |
$34.16M +5.9% |
$32.26M +27.1% |
$25.38M | — |
| Net Income | -$4.31M -121.5% |
$20.11M +464.6% |
$3.56M -60.0% |
$8.90M +74.9% |
$5.09M +327.1% |
-$2.24M +75.9% |
| Diluted EPS | $0.00 -100.0% |
$0.02 | $0.00 -100.0% |
$0.01 | $0.00 | $0.00 +100.0% |
| Total Assets | $96.39M +15.2% |
$83.65M +104.6% |
$40.90M +16.4% |
$35.15M +34.2% |
$26.19M +4.9% |
$24.96M +2.3% |
| Cash and Equivalents | — | $7.11M -9.3% |
$7.83M -8.2% |
$8.54M +167.3% |
$3.19M +182.1% |
$1.13M -50.3% |
| Stockholders Equity | $53.52M -7.1% |
$57.58M +98.8% |
$28.96M +14.8% |
$25.22M +56.2% |
$16.15M +51.6% |
$10.66M +524.9% |
| R&D Expense | $7.96M +15.7% |
$6.88M +11.0% |
$6.20M +53.0% |
$4.05M -20.8% |
$5.11M -7.6% |
$5.53M -27.2% |
| Operating Income | $19.60M +81.7% |
$10.79M +193.5% |
$3.68M -27.5% |
$5.07M +140.9% |
$2.10M +192.1% |
-$2.29M +75.0% |
| Gross Profit | $40.09M +52.1% |
$26.36M +58.8% |
$16.59M +12.2% |
$14.80M +24.7% |
$11.87M +48.7% |
$7.98M +178.2% |
| Shares Outstanding | 1.07B +0.0% |
1.07B +5.4% |
1.01B +0.3% |
1.01B +0.2% |
1.01B +20.1% |
840.40M +1.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $31.59M | +119.9% | -13.0% |
| Revenue (ASC 606) | December 31, 2025 | $31.59M | +119.9% | -13.0% |
| Net Income | December 31, 2025 | $18.59M | +270.7% | +35.7% |
| Diluted EPS | December 31, 2025 | $0.01 | +200.0% | +0.0% |
| Total Assets | December 31, 2025 | $126.41M | +39.3% | +7.8% |
| Cash and Equivalents | December 31, 2023 | $5.82M | -67.5% | -32.8% |
| Stockholders Equity | December 31, 2025 | $80.31M | +120.4% | +30.4% |
| R&D Expense | December 31, 2025 | $1.04M | -42.0% | -24.9% |
| Operating Income | December 31, 2025 | $9.01M | +721.0% | +9.7% |
| Gross Profit | December 31, 2025 | $12.95M | +111.7% | -8.0% |
| Shares Outstanding | December 31, 2025 | 1.07B | +0.6% | +0.1% |
- ELITE PHARMACEUTICALS INC /NV/ reported Total Revenue of $84.04 million for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +48.4% in Total Revenue compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported Revenue (ASC 606) of $84.04 million for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +48.4% in Revenue (ASC 606) compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported Net Income of -$4.31 million for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed a decrease of -121.5% in Net Income compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported Diluted EPS of $0.00 per share for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed a decrease of -100.0% in Diluted EPS compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported Total Assets of $96.39 million for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +15.2% in Total Assets compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported Cash and Equivalents of $7.11 million for fiscal year 2024.
- ELITE PHARMACEUTICALS INC /NV/ showed a decrease of -9.3% in Cash and Equivalents compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported Stockholders Equity of $53.52 million for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed a decrease of -7.1% in Stockholders Equity compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported R&D Expense of $7.96 million for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +15.7% in R&D Expense compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported Operating Income of $19.60 million for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +81.7% in Operating Income compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported Gross Profit of $40.09 million for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +52.1% in Gross Profit compared to the prior fiscal year.
- ELITE PHARMACEUTICALS INC /NV/ reported Shares Outstanding of 1.07 billion shares for fiscal year 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: